Please assess the completion status of the following clinical trial:

Trial Title: Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of RA (2010 American College of Rheumatology \[ACR\]/European League Against Rheumatism \[EULAR\] criteria) and are ACR functional class I-III.~* Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥ 6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both screening and Day 1.~* Limited or no prior treatment with MTX~Key Exclusion Criteria:~* Previous treatment with any janus kinase (JAK) inhibitor~* Previous therapy for longer than 3 months with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) other than MTX or hydroxychloroquine~* Use of any licensed or investigational biologic disease-modifying antirheumatic drugs (DMARDs)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg + MTX (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
- Filgotinib 100 mg + MTX (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
- Filgotinib 200 mg Monotherapy (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
- MTX Monotherapy (Type: ACTIVE_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).